Do low-molecular-weight heparins improve the survival of cancer patients?
Marcello Di Nisio*, Harry R Buller and Ettore Porreca
Correspondence *Centro Servizi Biomedici Palazzina SEBI, Via dei Vestini, 66013 Chieti, Italy
Email marcellodinisio@hotmail.com
This article has no abstract so we have provided the first paragraph of the full text.
The study by Lee et al. suggests that a 6-month course of dalteparin might improve, compared with vitamin K antagonists (VKA), the 12-month survival of cancer patients without metastasis at the time of their VTE event. The mortality rate at 1 year was reduced by 50% in the dalteparin group as compared with the VKA group (P = 0.02). For the whole cancer population, as for the subgroup of cancer patients with metastatic disease, the overall survival was comparable between the two treatment groups.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.